Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease schizophrenia
Symptom C0679466|cognitive deficits
Sentences 145
PubMedID- 23308105 Our study replicates the findings of numerous studies that demonstrated the presence of neurocognitive deficits in patients with schizophrenia on most domains tested, including attention, vigilance, and immediate memory, working memory, delayed memory and executive function 1.
PubMedID- 25552433 Although a link between prefrontal gaba hypofunction and cognitive deficits associated with schizophrenia has been proposed, until recently there has been surprisingly little preclinical research investigating the contribution of the gaba transmission to cognitive functions governed by the frontal lobes.
PubMedID- 23104864 Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study.
PubMedID- 20451258 Growing interest in cognitive deficits associated with schizophrenia has led to the need for a clinician-friendly cognitive instrument.
PubMedID- 20688137 A case is made for reasons that the nrg-erbb signaling pathway constitutes a "biologically plausible" system for understanding the pathogenic mechanisms that may underlie the complex array of positive, negative and cognitive deficits associated with schizophrenia during development.
PubMedID- 22570726 Although evidence suggests that smoking may ameliorate a number of cognitive deficits associated with schizophrenia, the association between smoking and cognitive deficits has been under-examined among chinese patients.
PubMedID- 24124576 According to this hypothesis, the behavioral and cognitive deficits seen in patients with a schizophrenia spectrum disorder are caused by disturbed functional and/or anatomical communication between distant brain regions, which normally constitute a network.
PubMedID- 23618463 While environmental influences are widely suggested to play a contributory role in development of this illness, genetics and familial predisposition play a very significant role: a meta-analytic review on cognitive performance between relatives of schizophrenic patients and healthy control subjects demonstrated that the same cognitive deficits found in patients with schizophrenia are also found in non-affected relatives .
PubMedID- 22559128 cognitive deficits in schizophrenia are increasingly accepted as core features of this disorder that play a role as vulnerability indicators, as enduring abnormalities during clinical remission, and as critical rate-limiting factors in functional recovery.
PubMedID- 20300465 Neurocognitive deficits in schizophrenia (sz) are thought to be stable trait markers that predate the illness and manifest in relatives of patients.
PubMedID- 22405729 Background: the heterogeneity of symptoms and cognitive deficits in schizophrenia can be explained by abnormal connectivity between brain regions.
PubMedID- 25287873 This study aims to assess specificity and degree of cognitive deficits in inpatients with acute schizophrenia and unipolar major depression.
PubMedID- 21249164 Taken together, these findings suggest that ssr180711 has the potential to improve cognitive deficits associated with schizophrenia and ad.
PubMedID- 23172002 The deficits reported typically fall between 1 and 2 standard deviations below the mean of healthy controls.88,89 cognitive deficits in patients with schizophrenia are associated with inability to function in the community90 and, as a result, have been the focus of specific clinical interventions.91 measures of cognitive functioning have been shown to correlate with measures of brain structure in patients with schizophrenia and healthy controls.92–95 if progressive brain tissue loss occurs over the course of schizophrenia, one might predict that this would be accompanied by progressive deterioration in cognitive functioning.
PubMedID- 24953512 Then, we discuss the complex relationship between cognitive deficits in patients with schizophrenia, problems in task performance, and disease-related effects on brain activation measured by fmri.
PubMedID- 20661811 cognitive deficits in patients with schizophrenia constitute a limiting factor to the chances of rehabilitation of daily living abilities, like personal and relational autonomy and working ability.
PubMedID- 25553979 Conclusions: aberrant theta-band connectivity may represent a trait characteristic of schizophrenia associated with neurocognitive deficits.
PubMedID- 26433217 We analyzed the effects of 10-hz rtms to the left dlpfc on cognitive deficits in schizophrenia in a large-scale and multicenter, sham-controlled study.
PubMedID- 22695257 Cognitive remediation training has been shown to improve both cognitive and social cognitive deficits in people with schizophrenia, but the mechanisms that support this behavioral improvement are largely unknown.
PubMedID- 22659472 The cognitive deficits associated with schizophrenia are recognized as a core component of the disorder, yet there remain no available therapeutics to treat these symptoms of the disease.
PubMedID- 21702128 cognitive deficits in schizophrenia are the core symptoms of this disorder, and are strongly correlated with decreased qol in patients.
PubMedID- 24782733 Although the underlying mechanisms require further investigation, our data suggest that valproate has great potential for improving cognitive deficits in patients with schizophrenia, especially males with nrg1 haploinsufficiency.
PubMedID- 25750798 Cognitive remediation therapy (crt) has been proved to improve cognitive deficits in schizophrenia and to enhance functional outcomes of classical rehabilitation.
PubMedID- 22096516 The alpha7 nicotinic acetylcholine receptor (nachr) is a potential target for the treatment of cognitive deficits in patients with schizophrenia, adhd and alzheimer's disease.
PubMedID- 25803852 Lastly, we suggest that t-817ma could be a new candidate for the treatment of negative symptoms and cognitive deficits associated with schizophrenia and autism.
PubMedID- 20050718 Conclusions: the rbans highlighted the cognitive deficits in schizophrenia and bd patients compared to controls and also each other.
PubMedID- 22283751 Finally, progress in developing allosteric muscarinic receptor agonists and modulators will be discussed and it will be argued the muscarinic m1 receptor allosteric agonists and/or modulators may have the potential to improve the cognitive deficits associated with schizophrenia whilst muscarinic m4 receptor modulates may have antipsychotic effects.
PubMedID- 22906530 cognitive deficits associated with schizophrenia (cds) are implicated as a core symptom cluster of the disease and are associated with poor daily life functioning.
PubMedID- 23330829 Not surprisingly, such drugs have been utilized to treat cognitive deficits in patients with schizophrenia in a handful of clinical trials.
PubMedID- 20846272 Conclusion: cognitive deficits in schizophrenia might be driven by abnormal fronto-posterior communication.
PubMedID- 23630632 In addition, negative symptoms such as social withdrawal are related to cognitive deficits in patients with schizophrenia .
PubMedID- 21629446 Positive allosteric modulators (pams) of mglur5 receptor function were originally designed to indirectly increase nmda receptor function, and therefore possibly alleviate some of the cognitive deficits associated with schizophrenia in accordance with the nmda receptor hypofunction model of this disorder .
PubMedID- 25959604 Conclusion: the arcs may be sensitive to the cognitive deficits in outpatients with schizophrenia and an indicator of functional outcomes in this population.
PubMedID- 25142099 Objective: cognitive deficits in schizophrenia play a crucial role in its clinical manifestation and seem to be related to changes in the cholinergic system, specifically the action of acetylcholinesterase (ache).
PubMedID- 21956441 This study examined the effects of a sub-chronic ketamine treatment to model cognitive deficits associated with schizophrenia, and to evaluate the effectiveness of nicotine, antipsychotic clozapine, and the novel mglu2/3 agonist, ly404039, in restoring ost performance.
PubMedID- 20053170 cognitive deficits in patients with schizophrenia are the biggest obstacle to achieving an independent and productive lifestyle, with these deficits being refractory to current drug treatments.
PubMedID- 26164820 Metacognitive deficits predict future levels of negative symptoms in schizophrenia controlling for neurocognition, affect recognition, and self-expectation of goal attainment.
PubMedID- 25450228 cognitive deficits lie upstream of the liability for schizophrenia with about a quarter of the variance in liability to schizophrenia explained by variation in cognitive function.
PubMedID- 22408449 It is a compound found in pacific nemertine paranemertes peregrina and currently tested for treatment of alzheimer’s disease and cognitive deficits associated with schizophrenia .
PubMedID- 25773225 Fourthly, neurological side effects of antipsychotic drugs and their treatment are reviewed; and lastly, we discuss neurocognitive deficits in patients with schizophrenia and their treatment.
PubMedID- 22053182 cognitive deficits of patients with schizophrenia have been largely recognized as core symptoms of the disorder.
PubMedID- 24043839 Postmortem studies have suggested that cognitive deficits in schizophrenia are correlated with modifications in the number and size of inhibitory synapses.
PubMedID- 22407730 Trait-related cognitive deficits in schizophrenia and bipolar disorder may share major phenotypic similarity in later life.
PubMedID- 22456094 Given the effects of cognitive deficits associated with schizophrenia on functional disability, there remains an ongoing need to identify effective means of directly ameliorating them.
PubMedID- 19945256 Efforts to identify differential or core cognitive deficits in schizophrenia have been made for several decades, with limited success.
PubMedID- 22715980 In order to improve the methodological quality of the studies performed in the field of cognitive deficits of patients with schizophrenia, various factors should be taken into account and better managed in designing future studies.
PubMedID- 25871975 A genome-wide association study of cognitive deficits in patients with schizophrenia in japan found association with a missense genetic variant (rs7157599, asn8ser) in the delta(4)-desaturase, sphingolipid 2 (degs2) gene.
PubMedID- 23778581 Impairment of the gamma-aminobutyric acid (gaba) signaling system is believed to partially account for behavioral and cognitive deficits associated with schizophrenia and mood disorders.1, 2 reduction of gabaa mediated signal transmission has also been associated with anxiety, panic, impaired learning and memory.3, 4, 5 gabaa receptors are responsible for mediating the fast inhibitory action of gaba,6 and are important sites for clinical action of a number of drugs including benzodiazepines, barbiturates and anesthetics.
PubMedID- 20967473 Siuciak reviewed in 2008 the role of phosphodiesterases in psychosis and she concludes that both isoenzymes bear great potential for the treatment of positive symptoms, negative symptoms and/or cognitive deficits associated with schizophrenia (siuciak 2008).
PubMedID- 19665142 Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with dhea.

Page: 1 2 3